Purpose: To describe current knowledge leading to a better understanding of OA pain and potential therapeutic targets for symptom and structural modification. Methods: Narrative review. Results: Pain originates from the OA joint, mediated by primary nociceptive neurons that have been localised to the majority of articular structures. Fine, myelinated Ad fibres are localised to joint capsule, periosteum and muscles, whereas unmyelinated C fibres are most abundant with synovium and subchondral bone marrow spaces. Unmyelinated afferents predominantly accompany blood vessels, and serve both sensory (pain) and efferent (control of vascular tone, permeability and proliferation) functions. During OA, sensory nerves change in their distribution, growing with blood vessels into articular cartilage and the inner two thirds of knee menisci. Furthermore, peripheral sensory nerve function is augmented (peripheral sensitisation), accompanied by changes in ion channel phosphorylation, neuromodulator and neurotransmitter expression. Key drivers of peripheral sensitisation offer potential as novel therapeutic targets for OA pain, including nerve growth factor, calcitonin gene-related peptide, and pro-inflammatory cytokines. Neuronal and vascular functions are tightly integrated, with factors originally recognised in pain processing pathways also modulating vascular function, and others, such as vascular endothelial growth factor, now known to also play important roles in neuronal growth and sensitisation. The joint vasculature is key to maintaining articular health, by facilitating metabolic homeostasis, contributing to tissue repair and new bone formation. Inappropriate or inadequate vascular responses might lead to relative hypoxia and acidosis, loss of osteochondral integrity and persistent inflammation; each of which can exacerbate OA pain. Conclusions: Targeting the neurovascular plasticity that is observed in OA joints might not only afford short term pain relief, but also modify symptomatically relevant structural changes and therefore afford sustained reductions in the burden of OA. Osteoarthritis (OA), primarily characterized by cartilage degeneration, is caused by an imbalance between anabolic and catabolic factors. Here, we investigated the role of zinc (Zn2þ) homeostasis, Zn2þ transporters, and Zn2þ-dependent transcription factors in OA pathogenesis. Among Zn2þ transporters, the Zn2þ importer ZIP8 was specifically upregulated in OA cartilage of humans and mice, resulting in increased levels of intracellular Zn2þ in chondrocytes. ZIP8-mediated Zn2þ influx upregulated the expression of matrix-degrading enzymes (MMP3, MMP9, MMP12, MMP13, and ADAMTS5) in chondrocytes. Ectopic expression of ZIP8 in mouse cartilage tissue caused OA cartilage destruction, whereas Zip8 knockout suppressed surgically induced OA pathogenesis, with concomitant modulation of Zn2þ influx and matrix-degrading enzymes. Furthermore, MTF1 was identified as an essential transcription factor in mediating Zn2þ/ZIP8-induced catabolic factor expression, and genetic modulation of Mtf1 in mice altered OA pathogenesis. We propose that the zincZIP8MTF1 axis is an essential catabolic regulator of OA pathogenesis. Osteoarthritis has long been considered as a joint disease influenced by local factors only (such as overload, joint trauma or anatomical deformities) which would trigger cartilage, subchondral bone and synovial cells activation leading to the release of degradative mediators eventually destroying the matrix. More recently, observational and interventional experimental studies have shown that a systemic lowgrade inflammation component could play an additional role, at least in a subgroup of OA patients suffering from metabolic diseases like obesity, diabetes mellitus, lipid abnormalities or hypertension. Because of the recent knowledge about close connections between inflammation, metabolic diseases and the brain, the influence of nervous system pathways on initiation and/or progression of OA could be considered, too. In this lecture, these potential pathways involved in communications between OA joints and the nervous system will be presented. The role of the circadian rhythms and of the autonomic nervous system on the pathophysiology of OA will be particularly developed. Such an integrative vision of the OA process is changing our paradigm by including OA in the list of the metabolic diseases that could be influenced by the brain. If confirmed, this hypothesis could be a breakthrough for treating OA, by seeking new targets modulating these pathways. A cross-cutting approach of the pathophysiology of the disease is now inevitable for a step-forward in the treatment approach of OA in the future.
Purpose: To describe current knowledge leading to a better understanding of OA pain and potential therapeutic targets for symptom and structural modification. Methods: Narrative review. Results: Pain originates from the OA joint, mediated by primary nociceptive neurons that have been localised to the majority of articular structures. Fine, myelinated Ad fibres are localised to joint capsule, periosteum and muscles, whereas unmyelinated C fibres are most abundant with synovium and subchondral bone marrow spaces. Unmyelinated afferents predominantly accompany blood vessels, and serve both sensory (pain) and efferent (control of vascular tone, permeability and proliferation) functions. During OA, sensory nerves change in their distribution, growing with blood vessels into articular cartilage and the inner two thirds of knee menisci. Furthermore, peripheral sensory nerve function is augmented (peripheral sensitisation), accompanied by changes in ion channel phosphorylation, neuromodulator and neurotransmitter expression. Key drivers of peripheral sensitisation offer potential as novel therapeutic targets for OA pain, including nerve growth factor, calcitonin gene-related peptide, and pro-inflammatory cytokines. Neuronal and vascular functions are tightly integrated, with factors originally recognised in pain processing pathways also modulating vascular function, and others, such as vascular endothelial growth factor, now known to also play important roles in neuronal growth and sensitisation. The joint vasculature is key to maintaining articular health, by facilitating metabolic homeostasis, contributing to tissue repair and new bone formation. Inappropriate or inadequate vascular responses might lead to relative hypoxia and acidosis, loss of osteochondral integrity and persistent inflammation; each of which can exacerbate OA pain. Conclusions: Targeting the neurovascular plasticity that is observed in OA joints might not only afford short term pain relief, but also modify symptomatically relevant structural changes and therefore afford sustained reductions in the burden of OA.
I-15 ROLE OF ZN2þ IMPORT AND THE ZN2þ/ZIP8/MTF1 AXIS ON OA J.-S. Chun. Gwangju Inst. of Sci. and Technology (GIST), Gwangju, Republic of Korea Osteoarthritis (OA), primarily characterized by cartilage degeneration, is caused by an imbalance between anabolic and catabolic factors. Here, we investigated the role of zinc (Zn2þ) homeostasis, Zn2þ transporters, and Zn2þ-dependent transcription factors in OA pathogenesis. Among Zn2þ transporters, the Zn2þ importer ZIP8 was specifically upregulated in OA cartilage of humans and mice, resulting in increased levels of intracellular Zn2þ in chondrocytes. ZIP8-mediated Zn2þ influx upregulated the expression of matrix-degrading enzymes (MMP3, MMP9, MMP12, MMP13, and ADAMTS5) in chondrocytes. Ectopic expression of ZIP8 in mouse cartilage tissue caused OA cartilage destruction, whereas Zip8 knockout suppressed surgically induced OA pathogenesis, with concomitant modulation of Zn2þ influx and matrix-degrading enzymes. Furthermore, MTF1 was identified as an essential transcription factor in mediating Zn2þ/ZIP8-induced catabolic factor expression, and genetic modulation of Mtf1 in mice altered OA pathogenesis. We propose that the zincZIP8MTF1 axis is an essential catabolic regulator of OA pathogenesis. Osteoarthritis has long been considered as a joint disease influenced by local factors only (such as overload, joint trauma or anatomical deformities) which would trigger cartilage, subchondral bone and synovial cells activation leading to the release of degradative mediators eventually destroying the matrix. More recently, observational and interventional experimental studies have shown that a systemic lowgrade inflammation component could play an additional role, at least in a subgroup of OA patients suffering from metabolic diseases like obesity, diabetes mellitus, lipid abnormalities or hypertension. Because of the recent knowledge about close connections between inflammation, metabolic diseases and the brain, the influence of nervous system pathways on initiation and/or progression of OA could be considered, too. In this lecture, these potential pathways involved in communications between OA joints and the nervous system will be presented. The role of the circadian rhythms and of the autonomic nervous system on the pathophysiology of OA will be particularly developed. Such an integrative vision of the OA process is changing our paradigm by including OA in the list of the metabolic diseases that could be influenced by the brain. If confirmed, this hypothesis could be a breakthrough for treating OA, by seeking new targets modulating these pathways. A cross-cutting approach of the pathophysiology of the disease is now inevitable for a step-forward in the treatment approach of OA in the future.
I-18
"BONY" PHENOTYPE: WORTHWHILE AS THERAPEUTIC TARGET?
J.H. Tobias. Univ. of Bristol, Sch. of Clinical Sci., Bristol, United Kingdom
Background: Epidemiological studies suggest a positive relationship exists between bone mineral density (BMD) and incident osteoarthritis (OA), but the relationship with OA progression is less certain. To establish whether increased BMD is linked to a causal pathway for OA, we examined OA phenotypes in a unique cohort of individuals with high bone mass (HBM), in whom BMD is assumed to be elevated due to genetically increased rates of bone formation.
HBM and OA: We found that HBM cases had a higher prevalence of hip and knee joint replacement as compared with unaffected family controls. On analysing hip and knee radiographs, compared to a combination of family and population based controls, HBM was associated with an increased risk of osteophytes, but not joint space narrowing. Although HBM cases have an increased risk of obesity, these radiographic associations persisted after BMI adjustment. In further analyses we found that BMD and osteophytes are positively associated with the presence of radiographic enthesophytes, suggesting a more generalised tendency towards bone formation ('bone forming triad'). Taken together, these findings suggest that higher BMD has a causal role in hypertrophic forms of OA, as part of a bony phenotype characterised by a generalised increase in bone formation. As supported by other evidence which suggests that osteophytes directly contribute to pain in OA, there may be a case for developing specific therapeutic strategies for hypertrophic OA.
Targeting the bone phenotype in OA: (i) Biomechanical inputs: Since osteophytes develop in response to disordered biomechanical inputs, hypertrophic OA may preferentially respond to biomechanical interventions such as foot orthoses and muscle strengthening exercises.
(ii) Osteophyte growth: It may be possible to develop drug therapies which target growth of osteophytes (which arise from the periosteum and are produced via a process of endochondral bone formation), without influencing bone remodelling and affecting the risk of osteoporosis. Such an action might explain the beneficial effect of hormone replacement therapy in OA, given oestrogen suppresses aspects of endochondral bone formation and selectively inhibits bone formation at the periosteal surface.
(iii) Nociceptive pathways: Inhibition of inflammatory mediators arising from cartilage, which are thought to contribute to the pathogenesis of pain in OA, may be of little value in treating hypertrophic forms of the disease. However, unlike articular cartilage, subchondral bone and osteophytes are both innervated. Therefore, hypertrophic OA may be helped by inhibition of neuronal nociceptive pathways, for which a range of novel inhibitors are in development, intended to target peripheral pain fibres, spinal cord gate control at the level of the dorsal root ganglion and/or central pain processing. Conclusion: Further insights into the molecular processes which regulate osteophyte development and osteophytic nociception may be helpful in guiding the development of novel treatments for OA which act by targeting the bony phenotype.
I-19 GENETIC LINKS BETWEEN DEVELOPMENT AND OSTEOARTHRITIS: DIO2 GENE AND RISK FOR OSTEOARTHRITIS
I. Meulenbelt. Leiden Univ. Med. Ctr., Leiden, Netherlands
Previously, in the Genetics osteoARthritis and Progression (GARP) study the deiodinase iodothyronine type II (D2) gene (DIO2) was identified as an OA susceptibility gene with this finding confirmed in other studies especially, for hip OA in females. D2 is critical in maintaining the availability of intracellular active thyroid hormone 3,3',5-triiodothyronine (T3). In the growth plate, T3 initiates the terminal differentiation of hypertrophic chondrocytes, which is important for the subsequent formation of long bones. Notably, in end-stage versus non-OA cartilage, DIO2 expression was found to be highly upregulated whereas an allelic imbalance was shown for the rs225014 SNP; the mRNA with the OA risk allele 'C' was 30% more abundantly present in articular joint tissues than the wild-type allele 'T'. It was then shown that loss of epigenetic silencing of DIO2 with the OA pathology resulted in a more vivid up regulation of DIO2 particularly in carriers of this risk allele C. Given the function of T3 in the growth plate during development, such signalling in adult articular cartilage is likely detrimental. In this respect, further studies showed that cartilage specific induction of DIO2 expression in adult mice resulted in, OA characteristic, hypertrophic differentiation. Subsequently, in a human in vitro 3D chondrogenesis model of human bone-marrow derived mesenchymal stem cells it was shown that upregulation of DIO2 expression resulted in a marked reduction in the capacity of chondrocytes to deposit ECM components, concurrent with induction of OA-specific markers of cartilage matrix degeneration and mineralization. In contrast, inhibition of deiodinases contributed to prolonged 'healthy' cartilage homeostasis by virtue of a denser cartilage matrix structure with significant less cellular lacunae. In line with these findings, it was very recent shown that DIO2 knockout mice, have normal articular cartilage development yet, when subjected to a stringent running regime, appear to be protected against cartilage damage and had reduced severity of synovitis as compared to their wild type littermates. Together these studies show that loss of epigenetic control of the DIO2 gene with ongoing OA pathology affects the propensity of OA chondrocytes recuperate a growth plate morphology and exhibit debilitating expression. Furthermore, focused functional followup of OA susceptibility genes to elucidate underlying pathophysiological mechanisms may contribute to a desirable translation from genetic studies towards novel therapeutic options.
I-20 SHOULD OA RESEARCH FOCUS ON "MICE" OR "MEN"?
C.B. Little. Raymond Purves Lab., Kolling Inst., Univ. of Sydney, St.
Leonards, Australia
Purpose: To argue that osteoarthritis (OA) research should focus on "mice". Methods: Review the evidence that real and sustainable advances in management and treatment of OA in "men" will ultimately come from "mice", i.e. preclinical research.
Results: The current model for the discovery, development and translation of successful therapies for OA into clinical practice has clearly not been successful. The easy conclusion to draw would be that what works in "mice" is not relevant to "men", and to set aside our preclinical research efforts. In this presentation we will explore in more depth the reasons for translational failure in OA, and make the case that far from cutting preclinical research, we should increase our focus in this area. Conclusions: Preclinical "mice" research will provide the foundation on which rational and effective OA treatments in "men" will be based. Purpose: To argue that osteoarthritis research should focus on "men". Methods: Provide supportive evidence to support the case that osteoarthritis research should focus on human disease. The presentation will also respond to the arguments made that osteoarthritis research should focus on mice. Results: Given the burden of disease in humans and the limited source of research funding prioritization is required. A case will be made that too much emphasis is placed on research into mice and insufficient focus is made on human research. Conclusions: There is insufficient focus on human research into osteoarthritis and too great an emphasis is placed on research on mice.
I-22 OSTEOARTHRITIS: INSIGHTS INTO DISEASE INITIATION AND PROGRESSION FROM MR IMAGING
G. Gold. Stanford Univ. Dept. of Radiology, Stanford, CA, USA Purpose: Magnetic Resonance Imaging (MRI) has provided researchers with an opportunity to examine joints non-invasively. Both the morphology and composition of articular cartilage and other tissues can be measured using MRI. A variety of MRI contrast mechanisms exist that can give unique information about tissue composition. This information can gain insight into disease initiation and progression. Methods: Many different contrast mechanisms are useful with MRI to examine joint morphology. In general, three-dimensional approaches are superior for quantitative evaluation of cartilage volume and thickness. Three-dimensional spoiled gradient echo (SPGR, FLASH) with dark synovial fluid have been used extensively in multiple studies. Other methods with bright synovial fluid include balanced steady state free precession (bSSFP), dual-angle steady state (DESS) MRI, and vastly interpolate projection reconstruction (VIPR). Three-dimensional fastspin-echo (3D-FSE) is a new method that may enable cartilage morphology and semi-quantitative scoring of other structures with a single acquisition. Important in all of these cartilage studies are accurate image segmentation and registration. For imaging tissue composition, multiple approaches have proven useful. The collagen matrix of the cartilage and the meniscus can be evaluated with T2 relaxation time mapping, magnetization transfer, and
